南方医科大学学报

南方医科大学学报 ›› 2004, Vol. 24 ›› Issue (07): 841-842,844.

• • 上一篇    下一篇

超分割放射治疗结合化疗治疗Ⅲ期非小细胞肺癌70例临床分析

周同冲1, 郑剑霄2   

  1. 1. 广州市肿瘤医院放疗科, 广东, 广州, 510095;
    2. 广东省中医院肿瘤科, 广东, 广州, 510120
  • 出版日期:2004-07-20 发布日期:2004-07-20
  • 基金资助:
    收稿日期:2004-1-4。
    作者简介:周同冲(1965- ),男,1992年毕业于中山医科大学,硕士,副主任医师,电话:020-83595032-2041

Hyperfractionated radiation therapy combined with concomitant chemotherapy for inoperable stage Ⅲ non-small cell lung cancer: clinical analysis of 70 cases

ZHOU Tong-chong1, ZHENG Jian-xiao2   

  1. 1. 广州市肿瘤医院放疗科, 广东, 广州, 510095;
    2. 广东省中医院肿瘤科, 广东, 广州, 510120
  • Online:2004-07-20 Published:2004-07-20

PDF

935

摘要： 目的 评价超分割放射治疗结合化疗治疗不能手术的Ⅲ期非小细胞肺癌(NSCLC)的疗效。方法 将70例不能手术的Ⅲ期NSCLC患者随机均分为治疗组和对照组,治疗组采用超分割放射治疗,对照组采用常规放疗,评价并比较两组疗效。结果 治疗组和对照组的总有效率分别为60.0%和40.0%(P=0.031,有显著性差异),完全缓解率分别为8.6%和5.7。治疗组和对照组的中位生存期和1、2年生存率分别为12.8个月vs 9.4个月、48.6%vs 34.3%、25.7%vs 17.1%,无显著性差异。主要的毒副作用是骨髓抑制、放射性食管炎。结论 超分割放射治疗结合同期化疗提高了不能手术的Ⅲ期NSCLC的近期有效率,但未能改善生存率。

Abstract: Objective To evaluate the effect of hyperfractionated radiation therapy and concomitant chemotherapy for inoperable stage Ⅲ non-small cell lung cancer (NSCLC). Methods Seventy patients were ramdomized equally into two group. The therapy group received radiotherapy with hyperfractionated radiation therapy combined with concomitant chemotherapy, and the control group was treated with chemotherapy only. Result The overall response rate, including the rate of both complete (CR) and partial responses (PR), in the therapy group was 60.0% with a CR rate of 8.6%. The overall response rate in the control group was 40.0% with a CR rate of 5.7%. The difference in overall response rate was statistically significant between the two groups (P<0.05). The median survival time, 1- and 2-years survival rate were 12.8 months, 48.6%, and 25.7%, respectively, in the hyperfractionatated radiotherapy group, and 9.4 months, 34.3%, and 17.1%, respectively, in the chemotherapeutic group (P=0.031). The major toxic effects of the chemotherapy were myelosuppression and radiation esophagitis. Conclusion Hyperfractionated radiation therapy plus concomitant chemotherapy with paclitaxel for inoperable stage Ⅲ NSCLC improves the short-term response of the patients, but fail to raise the survival rate.

中图分类号: